

Clostridium difficile diarrhoea

A side effect of health care

CHRIS KIELY BMedSc, MB BS; PAUL PAVLI MB BS(Hons), PhD, FRACP

Clostridium difficile is the most common bacterial cause of antibiotic-associated diarrhoea. Treatment with metronidazole is usually successful. Recurrence is common, and a variety of treatment options exist, from antibiotics to faecal microbial transplantation.

PAGE PROOFS:

Please return comments by THURSDAY 30 OCTOBER or earlier if at all possible.

Please note that this proof has not yet been proofread and the layout is rough at present and will be fine tuned. Many thanks.

Dr Kiely is an Advanced Trainee in Gastroenterology and Hepatology; and Dr Pavli is a Senior Staff Specialist in the Gastroenterology and Hepatology Unit, Canberra Hospital, ACT.

Series Editor: Associate Professor Simone Strasser, MD, FRACP, Clinical Associate Professor, Central Clinical School (Medicine), University of Sydney; and Senior Staff Specialist, AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW.



The views published in this Series are those of the authors and not necessarily indicative of those held by all members of the Digestive Health Foundation or GESA.

GASTROENTEROLOGY CLINIC



REMEMBER

- Depending on the antibiotic, between 5 and 25% of patients prescribed a course of antibiotics will experience diarrhoea. *Clostridium difficile* is the most commonly identified bacterial cause, accounting for 10 to 20% of cases. Severe *C. difficile* infection can lead to toxic megacolon, perforation and death through enterotoxin-mediated inflammation.
- Rates of *C. difficile* colonisation range from 5% in healthy adults up to 50% in health care workers, nursing home residents and hospitalised patients.
- *C. difficile*-associated diarrhoea (CDAD) generally requires a disturbance of the faecal microbiota (most commonly caused by antibiotic use) and colonisation through the faecal–oral route. *C. difficile* spores are detectable on the hands, stethoscopes and clothing of healthcare workers and can persist for months on objects such as toilets and other hospital furnishings.
- Soap and water are effective for removing spores from hands, but alcohol-based hand washes are not. Ten per cent hypochlorite solution (bleach) is effective for environmental cleaning.
- The risk of developing CDAD is increased seven to 10 times in the month following a course of antibiotics and persists for up to three months. Antibiotics most associated with CDAD include penicillins, cephalosporins, clindamycin and fluoroquinolones. Concomitant use of probiotics does not reduce the risk of CDAD in patients prescribed a course of antibiotics.
- Although most CDAD is associated with recent hospitalisation, community-acquired CDAD is increasing in incidence and accounts for up to 45% of cases. Proton pump inhibitor use is linked to CDAD even in patients who have not been exposed to antibiotics. Other risk factors include age over 65 years, enteral feeding, gastrointestinal surgery, obesity, chemotherapy and haematopoietic stem cell transplantation. Patients with inflammatory bowel diseases have both an increased incidence and mortality associated with CDAD.

- Recurrent CDAD is more likely in patients aged over 75 years, those who have renal impairment and those who have a stool frequency of greater than 10 per day at the beginning of the illness.
- Non-toxicogenic *C. difficile* does not cause CDAD and does not require treatment. Toxin A ('enterotoxin') causes inflammation, mucosal injury and intestinal fluid secretion through neutrophil activation and cytokine upregulation. Toxin B ('cytotoxin') is 10 times more potent. A hypervirulent strain of *C. difficile* (NAP1/BI/027) that produces an additional 'binary toxin' is associated with increased mortality.

ASSESSMENT

- Patients with new-onset watery diarrhoea and abdominal cramps should be assessed for CDAD, especially if they have been hospitalised or had a course of antibiotics.
- Signs of severe disease include diffuse tenderness, distension, temperature over 38.5°C and leucocytosis (more than 15 x10⁹ white cells/L). Patients with severe disease are at risk of developing fulminant colitis requiring emergency colectomy and should be admitted to hospital.
- Stool testing should be carried out. Most pathology laboratories test for *C. difficile* only if specifically requested. The tests usually performed include:

- enzyme immunoassay (EIA) for glutamate dehydrogenase (an essential enzyme); this test cannot distinguish between toxigenic and nontoxigenic *C. difficile* but is useful before specific EIA toxin testing
- EIA for toxins A and B, which has reasonable sensitivity (75%) and good specificity (99%)
- polymerase chain reaction (PCR) tests for toxins A and B, which are sensitive and specific but are more expensive than EIA
- faecal culture and toxin studies using cell culture cytotoxicity assays; these are the 'gold standard' but require more than 48 hours for a result.

- Colonoscopy (which may be limited to inspection of the rectum and sigmoid) should be considered if:
 - stool tests are negative despite high suspicion for CDAD
 - an urgent diagnosis is required or
 - the presentation is atypical, such as ileus.
- Pseudomembranes are a common finding in CDAD. These consist of serum proteins, mucus and inflammatory cells (Figures 1 and 2).
- CDAD recurs in 20% of patients even after effective initial treatment. Recurrence is usually due to relapse; spores are not killed by antibiotic treatment and can germinate after cessation of treatment. Retesting is required only if symptoms persist, as asymptomatic carriage of *C. difficile* may occur after treatment and does not itself require treatment.

MANAGEMENT

First-line therapy

- First-line therapy for mild to moderate CDAD is discontinuation of the antibiotic (if possible) and oral metronidazole (400 mg three times daily for 10 days).
- Severe CDAD is treated with oral vancomycin (125 mg four times daily

Are your ED[†] patients living with LUTS/BPH[‡]?

[†]Erectile Dysfunction.
[‡]Lower Urinary Tract Symptoms associated with Benign Prostate Hyperplasia.

Please review Full Product Information before prescribing. For PBS Information please refer to the Primary Advertisement in this publication.

Cialis (tadalafil) is a registered trademark of Eli Lilly and Company. Eli Lilly Australia Pty Ltd
 ABN 38 000233 982. Telephone 02 8326 4444. 112 Wharf Road, West Pye NSW 2114. AUCL2004010
 Date of Preparation Jan 2014. 384
 LIL306129MT-1/3

Lilly



Figure 1. Endoscopic image of the colon in a patient with pseudomembranous colitis. Note the pseudomembranes covering the colonic mucosa.




Figure 2. Low magnification photomicrograph of a section of colonic epithelium from a patient who required a colectomy for severe pseudomembranous colitis. Note the characteristic appearance of a 'volcanic eruption' (V) from the epithelial layer (E), comprising karyorrhectic debris and neutrophils within a pseudomembrane (P), which exudes from degenerated crypts.

(IMAGE COURTESY OF DR MITALI FADIA, DEPARTMENT OF ANATOMICAL PATHOLOGY, CANBERRA HOSPITAL, ACT.)

for 10 days), which has low intestinal absorption and achieves high concentrations in the bowel.

- Complicated CDAD (with toxic megacolon, ileus) is treated using intravenous metronidazole (500 mg three times daily) and oral or rectal vancomycin (500 mg four times daily).
- Other options for severe disease include tigecycline and intravenous immunoglobulins, which may provide passive immunotherapy against toxins A and B.

Treatment of relapse and recurrence

- Twenty per cent of patients will have a relapse, and 60% of these will have further recurrences, usually within two months of the initial infection. An expert opinion is recommended in the case of recurrence.
- Treatment of relapse or recurrence is with metronidazole or vancomycin. Fidaxomicin (200 mg twice a day orally for 10 days), a member of a new family of antibiotics termed macrocycles, is as effective as vancomycin for recurrence.
- A tapered regimen of vancomycin is

sometimes used, which targets persisting spores. This would usually be undertaken with the advice of an infectious diseases physician.

- In specialised centres, recurrent CDAD can be treated using faecal microbial transplantation, which can be more effective than further antibiotic therapy. Donor stool is sourced from a household member who has not had recent exposure to antibiotics or from a universal donor. Donors are screened for bloodborne and intestinal infections.

Prevention

- Patients who recover from CDAD and subsequently require antibiotic therapy for another condition should be monitored carefully. Antibiotics that carry a lower risk of CDAD (e.g. aminoglycosides, tetracyclines and metronidazole) should be considered over those with a higher risk.
- Prevention of the spread of spores is vital to reducing the incidence of CDAD. The key aspects are:
 - isolation of affected patients
 - effective hand washing and

– environmental decontamination.

- Health care workers in contact with affected patients should wash their hands with soap and water as alcohol-based hand washes are ineffective. Gloves and gowns should be worn. Contaminated furnishings and equipment should be cleaned using 10% bleach.

MT

FURTHER READING

- Bartlett J. Antibiotic-associated diarrhea. *N Engl J Med* 2002; 346: 334-339.
- Cheng A. Australasian Society for Infectious Diseases guidelines for the diagnosis and treatment of *Clostridium difficile* infection. *Med J Aust* 2011; 194: 353-358.
- Kachrimanidou M. *Clostridium difficile* infection: a comprehensive review. *Crit Rev Microbiol* 2011; 37: 178-187.
- Lee CH. The outcome and long-term follow-up of 94 patients with recurrent and refractory *Clostridium difficile* infection using single to multiple fecal microbiota transplantation via retention enema. *Eur J Clin Microbiol Infect Dis* 2014; 33: 1425-1428.
- van Nood E. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med* 2013; 368: 407-415.

COMPETING INTERESTS: None.